A BioMarin Pharmaceutical deal last year brought the company a late-stage therapy that fit its extensive enzyme replacement experience while also offering the potential to become the first treatment for

Nourish, a metabolic health clinic, announced Tuesday that it raised $100 million in Series C funding, which will help grow its clinical network. New York City-based Nourish has more than

Many conversations about the U.S. healthcare workforce start with the same word: shortage. Legislators want to fund more residency slots. Medical schools are expanding enrollment. Policy papers project the deficit

John Ayers believes most healthcare AI hype has not yet translated into meaningful patient impact — though he thinks that may soon change. This belief drove Ayers and a team

In a recent letter, a group of 48 employer and consumer organizations are calling on the Trump Administration to strengthen oversight of certified independent dispute resolution (IDR) entities, which resolve

Despite the availability of many hypertension drugs, many people find these medicines don’t work well enough. A first-in-class AstraZeneca medication now has FDA approval, giving patients a new way to

This month, Cigna announced during its first quarter earnings call that it is exiting its individual exchange business or the Obamacare exchanges at the end of the year, affecting 369,000

Biopharmaceutical companies aim to make taking a biologic drug as simple as possible for patients, marketing many of these chronically administered medicines in self-injection pens for quick and easy dosing.

Every year, seasonal pressures stretch hospital capacity to its limits. Periods of increased admissions often force hospitals to postpone elective surgeries as staff and resources are diverted to more urgent

Today’s healthcare leaders are largely being sold “AI-as-a-service”: SaaS products that solve a specific task and connect to other SaaS products, enhanced with AI, as a wave of startups pushes